Fundz

Orchestra BioMed Holdings

London, England, United Kingdom · Biotechnology, Health Care, Manufacturing

Orchestra BioMed Holdings, Inc. is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Its lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, and it is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of ather

You have opened 5 full company profiles today. Create an account to keep reading them. Create an account

Key facts

Headquarters
London, England, United Kingdom
Employees
70
Industries
Biotechnology, Health Care, Manufacturing
Status
Public (OBIO)
Website
www.orchestrabiomed.com
LinkedIn
Company page

Recent activity at Orchestra BioMed Holdings

  • : SEC 8-K (1.01): On November 5, 2026, Orchestra BioMed Holdings, Inc. entered into an underwriting agreement with Piper Sandler & Co. and TD Securities (USA) LLC for an underwritten public offering of 15,000,000 shares of common stock at a price of $5.00 per share. The offering, which closed on November 9, 2026, raised approximately $86.3 million in gross proceeds. Additionally, the underwriters were granted a 30-day option to purchase up to 2,250,000 additional shares, which was exercised on November 6, 2026. The net proceeds will be used to fund the Company's various programs, including the BACKBEAT global pivotal trial for hypertension and research for other product candidates, along with working capital and general corporate purposes.
  • : SEC 8-K (7.01): On October 1, 2026, Orchestra BioMed Holdings, Inc. issued a press release announcing that it exceeded the enrollment target in the BACKBEAT Global Pivotal Trial of its AVIM Therapy. This event is significant as it suggests positive progress in their clinical trial, which could impact future developments and investor confidence. The announcement indicates strong performance in achieving trial recruitment objectives, which is crucial for the advancement of the therapy towards regulatory approval. The release serves as a Regulation FD disclosure and can be found in Exhibit 99.1 attached to this report.
  • : SEC 8-K (7.01):

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

About Orchestra BioMed Holdings: questions and answers

What does Orchestra BioMed Holdings do?

Orchestra BioMed Holdings, Inc. is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with leading medical device companies. Its lead product candidate is atrioventricular interval modulation (AVIM) therapy for the treatment of hypertension, and it is also developing Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of ather

Where is Orchestra BioMed Holdings headquartered?

Orchestra BioMed Holdings is headquartered in London, England, United Kingdom.

How many employees does Orchestra BioMed Holdings have?

Orchestra BioMed Holdings has about 70 employees.

What is the latest news on Orchestra BioMed Holdings?

On Sep 8, 2026, SEC 8-K (1.01): On November 5, 2026, Orchestra BioMed Holdings, Inc. entered into an underwriting agreement with Piper Sandler & Co. and TD Securities (USA) LLC for an underwritten public offering of 15,000,000 shares of common stock at a price of $5.00 per share. The offering, which closed on Novem

Is Orchestra BioMed Holdings a public company?

Yes. Orchestra BioMed Holdings is publicly traded under the ticker OBIO.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Orchestra BioMed Holdings across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.